

1 **Preliminary optimisation of a simplified sample preparation method to**
2 **permit direct detection of SARS-CoV-2 within saliva samples using reverse-**
3 **transcription loop-mediated isothermal amplification (RT-LAMP)**

4
5 *Emma L. A. Howson^{1,2}, *Stephen P. Kidd³, Jason Sawyer⁴, Claire Cassar⁴, David Cross⁴, Tom Lewis⁴,
6 Jess Hockey⁴, Samantha Rivers⁴, Saira Cawthraw⁴, Ashley Banyard⁴, Paul Anderson⁴, Sabah Rahou⁴,
7 Michael Andreou⁵, Nick Morant¹, Duncan Clark¹, Charlotte Walsh¹, Shailen Laxman⁵, Rebecca
8 Houghton³, Joanne Slater-Jefferies⁶, Paula Costello⁷, Ian Brown⁴, Nicholas Cortes^{3,8}, Keith M.
9 Godfrey^{7,9}, *Veronica L. Fowler^{3,10}

10
11 ¹GeneSys Biotech Limited, Camberley, Surrey, UK

12 ²The Pirbright Institute, Ash Road, Woking, Surrey, UK

13 ³Hampshire Hospitals NHS Foundation Trust, Department of Microbiology, Basingstoke and
14 Winchester, UK

15 ⁴Animal and Plant Health Agency, New Haw, Addlestone, Surrey, UK

16 ⁵OptiSense Limited, Horsham, West Sussex, UK

17 ⁶National Biofilms Innovation Centre, University of Southampton, UK

18 ⁷MRC Lifecourse Epidemiology Unit, University of Southampton, UK

19 ⁸Gibraltar Health Authority, Gibraltar, UK

20 ⁹NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital
21 Southampton, UK

22 ¹⁰Eco Animal Health, The Grange, 100 The High Street, London, N14 6BN, UK

23
24 *Corresponding author: E-mail: veronica.fowler@ecoanimalhealth.com

25
26 *Joint first authors

27
28 **Running title**

29 RT-LAMP assay for the rapid detection of SARS-CoV-2 in saliva.

30
31 **Keywords**

32 SARS-CoV-2, COVID-19, RT-LAMP, rapid diagnostics, near patient testing, direct detection

36 **Abstract**

37 We describe the optimization of a simplified sample preparation method which permits rapid and
38 direct detection of SARS-CoV-2 RNA within saliva using reverse-transcription loop-mediated
39 isothermal amplification (RT-LAMP). Treatment of saliva samples prior to RT-LAMP by dilution 1:1 in
40 Mucolyse™, followed by dilution (within the range of 1 in 5 to 1 in 40) in 10% (w/v) Chelex® 100 Resin
41 and a 98°C heat step for 2 minutes enabled detection of SARS-CoV-2 RNA in all positive saliva samples
42 tested, with no amplification detected in pooled negative saliva. The time to positivity for which SARS-
43 CoV-2 RNA was detected in these positive saliva samples was proportional to the real-time reverse-
44 transcriptase PCR cycle threshold (C_T), with SARS-CoV-2 RNA detected in as little as 05:43 (C_T 21.08),
45 07:59 (C_T 24.47) and 08:35 (C_T 25.27) minutes, respectively. The highest C_T where direct RT-LAMP
46 detected SARS-CoV-2 RNA was 31.39 corresponding to a 1 in 40 dilution of a positive saliva sample
47 (1:1 in Mucolyse™) with a starting C_T of 25.27. When RT-LAMP was performed on pools of SARS-CoV-
48 2 negative saliva samples spiked with whole inactivated SARS-CoV-2 virus, RNA was detected at
49 dilutions spanning 1 in 5 to 1 in 160 representing C_T 's spanning 22.49-26.43. Here we describe a simple
50 but critical rapid sample preparation method which can be used up front of RT-LAMP to permit direct
51 detection of SARS-CoV-2 within saliva samples. Saliva is a sample which can be collected non-invasively
52 without the use of highly skilled staff and critically can be obtained from both healthcare and home
53 settings. Critically, this approach overcomes both the requirement and validation of different swabs
54 and the global bottleneck in obtaining RNA extraction robots and reagents to enable molecular testing
55 by PCR. Such testing opens the possibility of public health approaches for effective intervention to
56 control the COVID-19 pandemic through regular SARS-CoV-2 testing at a population scale, combined
57 with isolation and contact tracing for positive cases.

58

59

60 Introduction

61 The COVID-19 pandemic caused by the SARS-CoV-2 virus poses a profound global threat to
62 communities, economic activity and healthcare systems. It is generally accepted that a safe and
63 efficacious vaccine will not be widely available in the immediate future whilst uncertainty remains
64 over the trajectory of the pandemic. Moreover, herd immunity from a high proportion of the
65 population having become immune to SARS-CoV-2 is not thought to be a viable public health strategy
66 by most observers. One public health approach that has been advocated for suppression of the COVID-
67 19 pandemic is regular SARS-CoV-2 testing at a population scale, combined with isolation and contact
68 tracing for positive cases¹. Such an approach requires a rapid relatively inexpensive diagnostic test for
69 the presence of the SARS-CoV-2 virus, ideally based on samples that can be simply collected in both
70 health care and non-health care (e.g. home) settings².

71

72 The current international gold standard for diagnosis of infection with SARS-CoV-2 is detection of viral
73 RNA by real-time Reverse Transcriptase Polymerase Chain Reaction (rRT-PCR) from a naso-pharyngeal
74 or oropharyngeal swab in viral transport medium³. However, the procedure for collecting a good
75 quality sample using this approach requires a degree of training and skill, potentially exposes the
76 sampler to infectious droplets, and can be uncomfortable and traumatic for the patient, especially if
77 undertaken frequently. Critically, supply issues during the pandemic have led to bottlenecks in the
78 availability of reagents for molecular assays, leading to demand for bespoke extraction kits far
79 outweighing the available supply and hampering testing efforts globally. Alongside this, the
80 requirement for swab testing has led to key manufacturers being unable to cope with swab demand
81 for patient sampling^{4,5}. This has meant that laboratories have had to undertake frequent and time-
82 consuming assay validation on different swab types. As such, exploring alternative sample types and
83 RNA detection methods that circumvent the issues above is an attractive solution.

84

85 Saliva is a sample which shows promise for infection diagnostics, including for detection of
86 coronaviruses and has been shown as a site where SARS-CoV-2 is found in early infection^{6,7}. Collection
87 of saliva is straightforward and can be done by the patient themselves using a drooling technique, and
88 collection devices include a simple, widely available, universal plastic container.

89

90 Reverse-Transcription Loop-mediated isothermal AMPlification (RT-LAMP) is a highly sensitive
91 reverse-transcription, autocycling, isothermal, strand displacement nucleic acid amplification
92 technology⁸ which is more resistant to inhibitors than rRT-PCR, enabling simplification and even
93 removal of the extraction procedure⁹⁻¹¹. LAMP technologies have been applied for the detection of a
94 wide range of pathogens¹²⁻¹⁴ including positive-sense RNA viruses¹⁰ and has been used extensively in
95 the veterinary^{15,16} and plant industry¹⁷⁻¹⁹ and more recently as a human diagnostic^{12,20,21}. At the height
96 of the SARS-CoV-2 epidemic in the UK in early 2020, Hampshire Hospitals NHS Foundation Trust (HHFT)
97 validated a novel RT-LAMP assay for the detection of SARS-CoV-2 RNA within nasopharyngeal and
98 oropharyngeal swabs either directly from swab, or following RNA extraction²². For direct detection of
99 SARS-CoV-2 RNA from swab, a simple dilution of 1 in 20 of the viral transport media in nuclease free
100 water (NFW) was shown to be sufficient to overcome inhibition and to achieve sensitivity (DSe) and
101 specificity (DSp) of 67% and 97%, respectively. When setting rRT-PCR cycle threshold (C_T) cut-offs of
102 ≤ 33 and ≤ 25 , the DSe increased to 75% and 100%, respectively, with the specificity retained. Within
103 this first study²², preliminary evaluation of Direct RT-LAMP for detection of SARS-CoV-2 in other clinical
104 samples was performed using fourteen saliva samples collected from hospital in-patients confirmed
105 from paired swabs as positive and negative for SARS-CoV-2. Using a 1 in 20 dilution of saliva in NFW,
106 SARS-CoV-2 RNA was detected as expected in four of the positive swab samples but was unexpectedly
107 detected in only two of the saliva samples. This indicated that more work was required to optimize
108 the crude sample preparation method for detection of SARS-CoV-2 in saliva. Herein we describe the
109 further optimisation of a simple sample preparation method to permit direct detection of SARS-CoV-
110 2 within saliva samples using Direct RT-LAMP.

111 **Materials and Methods**

112 ***Virus isolates and clinical specimens***

113
114 Optimisation of Direct RT-LAMP for detection of SARS-CoV-2 RNA in saliva was performed using three
115 SARS-CoV-2 positive saliva samples collected from symptomatic patients at Hampshire Hospitals NHS
116 Foundation Trust (HHFT) (n=1) and University Hospital Southampton (UHS) (n=2) who had previously
117 had rRT-PCR positive SARS-CoV-2 positive naso-pharyngeal samples. An additional 15 SARS-CoV-2
118 negative saliva samples collected from asymptomatic UHS healthcare staff were used to prepare a
119 pooled sample for specificity analysis. For spiking experiments, one pool of 25 SARS-CoV-2 negative
120 saliva samples from asymptomatic UHS staff, and a second pool of 5 SARS-CoV-2 negative saliva
121 samples also from asymptomatic UHS staff, were used to prepare pooled samples for spiking with
122 whole inactivated virus (SARS-CoV-2 at $\sim 1 \times 10^5$ TCID₅₀/ml was inactivated using beta-propiolactone
123 [BPL]). Collection of saliva involved the patient providing a fresh saliva sample into a 10 ml universal
124 container. Each positive saliva sample was diluted 1:1 in Mucolyse™ (active ingredient: dithiothreitol,
125 Pro-Lab Diagnostics, UK) prior to dilution in either NFW or 10% Chelex® 100 Resin (Bio-Rad
126 Laboratories, Watford, UK)²³. Mucolyse™ was also added 1:1 to the final pool of negative saliva
127 samples and the second SARS-CoV-2 spiked pool.

128

129 ***RNA extraction***

130 The saliva sample collected within the HHFT was extracted using the Maxwell® RSC Viral Total Nucleic
131 Acid Purification Kit (Promega UK Ltd., Southampton, UK) according to manufacturer's instructions.
132 Briefly, 200 µl of sample was added to 223 µl of prepared lysis solution (including 5 µl per reaction of
133 Genesig® Easy RNA Internal extraction control, Primerdesign Ltd, Chandler's Ford, UK). Samples were
134 then inactivated for 10 minutes at room temperature within the safety cabinet and 10 minutes at 56°C
135 on a heat block before automated RNA extraction using a Maxwell® RSC 48 Instrument (Promega UK
136 Ltd., Southampton, UK). RNA was eluted in 50 µl of NFW.

137

138 The saliva samples collected from UHS were extracted using the MagMAX™CORE Nucleic acid
139 purification kit (Thermofisher). Briefly, 10 µl of sample (diluted in 190 µl DEPC treated water) was
140 added to 700 µl of prepared lysis solution. Samples were then inactivated for 10 minutes at room
141 temperature within the safety cabinet before automated RNA extraction using a KingfisherFlex
142 (Thermofisher). RNA was eluted in 90 µl of NFW.

143

144 ***Real-time reverse-transcription PCR (rRT-PCR)***

145 All rRT-PCR assays were performed in single replicates using 5 µl of RNA template. The saliva sample
146 collected within the HHFT was analysed using the COVID-19 genesig® Real-Time PCR assay
147 (Primerdesign Ltd, Chandler's Ford, UK) according to the manufacturer's guidelines, on a MIC qPCR
148 Cycler (Bio Molecular Systems, London, UK). The cycling conditions were adjusted to the following: a
149 reverse-transcription (RT) step of 10 minutes at 55°C, a hot-start step of 2 minutes at 95°C, and then
150 45 cycles of 95°C for 10 seconds and 60°C for 30 seconds. The Genesig® COVID-19 positive control
151 included in the kit, a negative extraction control, and a no template control were also included on
152 each rRT-PCR run.

153

154 The saliva samples collected from the UHS and the spiked whole virus dilution series were tested using
155 the E gene RT-PCR as described previously (Corman et al.,2020) using the AgPath-ID™ PCR kit
156 (Thermofisher). Samples were run on an Aria qPCR Cycler (Agilent) and results analysed using the
157 Agilent AriaMX 1.5 software. The cycling conditions were adjusted to the following: a reverse-
158 transcription (RT) step of 10 minutes at 55°C, a hot-start step of 3 minutes at 94°C, and then 45 cycles
159 of 94°C for 15 seconds and 60°C for 15-30 seconds during data acquisition. The SARS-CoV2 positive
160 control RNA, a negative extraction control, and a no template control were also included on each rRT-
161 PCR run.

162

163

164 **Preparation of 10% (w/v) Chelex® 100 Resin**

165 10% (w/v) Chelex® 100 Resin was made up by resuspending Chelex® 100 Resin (200-400 mesh) (Bio-
166 Rad Laboratories, catalogue number #142-1253) in Milli-Q® water at 10% (w/v). The solution was
167 heated at 70°C for 30 minutes. Two washes in Milli-Q® water were performed by allowing the Chelex®
168 100 Resin to settle, removing the supernatant, adding Milli-Q® water to 10% (w/v) and shaking. After
169 a second wash, Milli-Q® water was added to give a final 10% Chelex® 100 (w/v) Resin solution.

170

171 **Reverse-transcription loop-mediated isothermal amplification (RT-LAMP)**

172 RT-LAMP reactions were performed using OptiGene Ltd. (Horsham, UK) COVID-19_Direct RT-LAMP
173 KIT-500 kit which targets the *ORF1ab* region of the SARS-CoV-2 genome.

174

175 Each RT-LAMP reaction consisted of: 17.5 µl of RT-LAMP Isothermal Mastermix (containing 8 units of
176 GspSSD2.0 DNA Polymerase, 7.5 units of Opti-RT reverse transcriptase and a proprietary fluorescent
177 dsDNA intercalating dye and a proprietary enhancing enzyme), 2.5 µl of 10X COVID-19 Primer Mix,
178 and 5 µl of RNA/sample. RT-LAMP reactions were performed in duplicate at 65°C for 20 mins on a
179 Genie® HT (OptiGene Ltd., UK). An exponential increase in fluorescence (ΔF) indicated a positive
180 reaction, which was quantified by a time to positivity (T_p) value, called at the point where the
181 fluorescence level on the amplification curve, crosses the threshold of 5000. To confirm the specificity
182 of the amplification reaction, an anneal curve was performed: RT-LAMP products were heated to 98°C
183 for 1 min, then cooled to 80°C decreasing the temperature by 0.05°C/s.

184

185 Genie® embedded software (OptiGene Ltd., UK) was utilised to analyse RT-LAMP results and define
186 thresholds for result calling. All RT-LAMP reactions were performed in duplicate, and a sample was
187 considered positive when a T_p was observed in at least one replicate with amplification above 5000
188 fluorescence points and had an anneal temperature of between 81.50°C and 84.05°C with a derivative
189 above 2500 F/°C.

190 For Direct RT-LAMP, 5 µl of saliva diluted in NFW or 10% (w/v) Chelex® 100 Resin spanning 1 in 5 to 1
191 in 640, with and without heat treatment (70°C for 4 minutes or 98°C for 2 mins) was added to the
192 reaction. Heating was performed on a dry heat block. The same treatments were applied to the saliva
193 pools spiked with whole inactivated virus and to the non-spiked negative saliva pool, however the first
194 spiked saliva pool was only titrated as far as 1 in 40 in the first instance. After addition to Direct RT-
195 LAMP all treatments were pooled according to dilution (e.g. all temperature treatments were pooled
196 according to the dilution) and extracted for rRT-PCR analysis (for the first spiked sample [Table 2],
197 saliva from each treatment was extracted separately for rRT-PCR analysis).

198

199 **Results**

200 ***Optimisation of the Direct-RT-LAMP***

201 Optimization of the Direct RT-LAMP assay for detection of SARS-CoV-2 was determined using three
202 positive saliva samples, a pool of non-spiked negative saliva and a pool of spiked saliva.

203 The three positive saliva samples diluted 1:1 in Mucolyse™ rRT-PCR C_T values were 21.08, 24.47 and
204 25.27 (Table 1). For the first spiked saliva pool, the whole inactivated virus spiked into saliva prior to
205 dilution rRT-PCR C_T was 26.70 (Table 2). For the second spiked saliva pool, the whole inactivated virus
206 spiked into saliva diluted 1:1 in Mucolyse™ (prior to further dilutions) rRT-PCR C_T was 22.86 (Table 3).

207

208 From rRT-PCR data samples were assessed for sensitivity using the Direct-LAMP protocol. Samples
209 were assessed in order of highest viral load by rRT-PCR (C_T 21.08: Table 1, Panel A) result to lowest (C_T
210 25.27: Table 1, Panel C).

211

212 The saliva sample with the highest viral load (C_T 21.08) when diluted in water was detected in
213 duplicate in five dilutions (1 in 40 to 1 in 640) without heat treatment, in all eight dilutions (1 in 5 to 1
214 in 640) following 70°C for 4 mins and in seven dilutions (1 in 5 to 1 in 320) following 98°C for 2 mins

215 (Table 1, Panel A). When diluted in 10% (w/v) Chelex® 100 Resin the same saliva sample (C_T 21.08) was
216 detected in duplicate in seven dilutions (1 in 10 to 1 in 640) without heat treatment and in all eight
217 dilutions (1 in 5 to 1 in 640) following either 70°C for 4 minutes or 98°C for 2 minutes (Table 1, Panel
218 A).

219

220 The saliva sample with a C_T of 24.47 when diluted in water was not detected in duplicate in any dilution
221 without heat or following 70°C for 4 mins (Table 1, Panel B). This sample was detected in duplicate in
222 three dilutions (1 in 5 to 1 in 20) only following 98°C for 2 mins (table 1). When diluted in 10% (w/v)
223 Chelex® 100 Resin the same saliva sample (C_T 24.47) was detected in duplicate in one dilution (1 in 20)
224 without heat treatment, in 4 dilutions (1 in 10 to 1 in 80) following 70°C for 4 minutes and in five
225 dilutions (1 in 5 to 1 in 40 and 1 in 160) following 98°C for 2 minutes (Table 1, Panel B).

226

227 The saliva sample with the lowest viral load (C_T 25.27) when diluted in water was not detected in
228 duplicate in any dilution without heat or following 70°C for 4 mins (Table 1, Panel C). This sample was
229 detected in duplicate in one dilution (1 in 5) only following 98°C for 2 mins (Table 1, Panel C). When
230 diluted in 10% (w/v) Chelex® 100 Resin the same saliva sample (C_T 25.27) was detected in duplicate in
231 two dilutions (1 in 40 and 1 in 80) without heat treatment, in no dilutions following 70°C for 4 minutes
232 and in four dilutions (1 in 5 to 1 in 40) following 98°C for 2 minutes (Table 1, Panel C).

233

234 The pool of saliva samples negative for SARS-CoV-2 was negative also on Direct RT-LAMP for all assay
235 conditions (data not shown as all samples reported a negative result).

236

237 The whole inactivate virus spiked into saliva with a C_T of 26.70 when diluted in water was detected in
238 duplicate at one dilution (1 in 40) without heat, in three dilutions (1 in 10, 1 in 20, 1 in 40) following
239 70°C for 4 mins and in two dilutions (1 in 5 and 1 in 10) following 98°C for 2 mins (Table 2). When
240 diluted in 10% (w/v) Chelex® 100 Resin the same saliva sample was detected in duplicate in two

241 dilutions (1 in 20 and 1 in 40) without heat treatment, in three dilutions (1 in 10, 1 in 20, 1 in 40)
242 following 70°C for 4 minutes and in all four dilutions (1 in 5 to 1 in 40) following 98°C for 2 minutes
243 (Table 2).

244

245 A further dilution series of SARS-CoV-2 inactivated whole virus was prepared to include the 1:1
246 Mucolyse™ dilution that is used for clinical samples and to extend beyond a 1 in 40 dilution to reach
247 the limit of detection of the Direct RT-LAMP assay. The whole inactivated virus spiked into saliva (C_T
248 of 22.86 when diluted in water was detected in duplicate at one dilution (1 in 80) without heat, in
249 three dilutions (1 in 5, 1 in 10 and 1 in 80) following 70°C for 4 mins and in three dilutions (1 in 5, 1 in
250 10 and 1 in 40) following 98°C for 2 mins (Table 3). When diluted in 10% (w/v) Chelex® 100 Resin the
251 same saliva sample was detected in duplicate in three dilutions (1 in 20, 1 in 40 and 1 in 80) without
252 heat treatment, in six dilutions (1 in 5 to 1 in 160) following 70°C for 4 minutes and in six dilutions (1
253 in 5 to 1 in 160) following 98°C for 2 minutes (Table 3).

254

255 **Discussion**

256 This study describes the rapid optimization of a method to permit direct detection of SARS-CoV-2 RNA
257 within saliva samples using RT-LAMP, without need for prior RNA extraction. Our previous publication
258 was focused on optimizing conditions for rapid detection of SARS-CoV-2 within viral transport media
259 from swabs samples²². In that publication, preliminary evaluation of the direct transfer of the swab
260 sample preparation method for comparable detection in paired saliva samples was poor, indicating
261 that a different sample preparation method would be required for optimal detection of SARS-CoV-2
262 RNA in crude saliva. In this study we show for the first time that the optimal sample preparation
263 method to allow SARS-CoV-2 RNA detection within crude saliva samples (1:1 mix of saliva and

264 Mucolyse™ (active ingredient dithiothreitol)) requires saliva dilution in 10% (w/v) Chelex® 100 Resin
265 and heating to 98°C 2 minutes prior to adding to the direct RT-LAMP reagents.

266

267 When using this approach SARS-CoV-2 RNA was reliably detected in duplicates for a wide range of
268 dilutions assessed from positive saliva samples with a starting C_T value of 21.08, 24.47 and 25.27. The
269 combination of a chelating resin (Chelex® 100 Resin) and heating the sample to 98°C successfully
270 overcame matrix inhibition and or matrix “protection” of viral capsid nucleic acid release which was
271 observed in the samples which did not receive this protocol. The time to positivity (speed at which
272 SARS-CoV-2 RNA was detected in saliva) was proportional to the “strength” of the saliva sample after
273 addition of 1:1 Mucolyse™ (active ingredient: dithiothreitol) as determined by real-time reverse-
274 transcriptase PCR with SARS-CoV-2 detected in a mean time of 05:55 (C_T 21.08), 08:39 (C_T 24.47) and
275 09:15 (C_T 25.27) minutes, respectively when using a dilution of 1 in 10 of saliva into 10% (w/v) Chelex®
276 100 Resin. Importantly, using this method, no amplification was detected in the negative pooled saliva
277 samples, confirming the compatibility of this sample preparation approach in maintaining specificity
278 of the assay.

279

280 Due to the lower prevalence of SARS-CoV-2 at the time of optimisation of this sample preparation
281 method, only three positive saliva samples were available for analysis. To strengthen conclusions
282 drawn from these clinical specimens, spiked dilution series of whole inactivated virus spiked into
283 pooled saliva were also evaluated with equivalent results obtained. This method should therefore be
284 translatable to saliva samples regardless of whether they are obtained from symptomatic or
285 asymptomatic patients.

286

287 Studies in macaque monkeys demonstrated that the salivary glands in the mouth are the first site in
288 the body to be affected by SARS-CoV infection²⁴ and several groups have reported high sensitivity and
289 specificity saliva of rRT-PCR for SARS-CoV-2 in COVID-19 patients^{25,26}. SARS-CoV-2 is therefore present

290 in saliva samples early in the course of infection and can be spread to other individuals efficiently
291 through salivary droplets generated when talking loudly or singing²⁷. Population screening of saliva
292 samples may therefore be an effective strategy to detect the important group of people who are
293 infectious but not yet symptomatic. There is also evidence that SARS-CoV-2 may be present in saliva
294 during the recovery phase from infection after upper respiratory samples have become negative²⁸,
295 making saliva an attractive sample type for identification of individuals in the population who could
296 transmit infection⁴.

297

298 These findings add to the increasing literature supporting saliva as a reliable sample type in which to
299 detect SARS-Cov-2 RNA. Using saliva samples collected in a simple collection pot, we have described
300 an approach that paves the way for a rapid diagnostic test for the presence of the SARS-CoV-2 virus
301 based on samples that can simply be collected at home or in other non-healthcare settings. Critically,
302 this approach overcomes both the requirement and validation of different swabs and the global
303 bottleneck observed in obtaining RNA extraction robots and reagents to enable molecular testing by
304 PCR. Such testing opens the possibility of public health approaches for suppression of the COVID-19
305 pandemic through regular SARS-CoV-2 testing at a population scale at relatively low cost, combined
306 with isolation and contact tracing for positive cases.

307

308 **Ethics**

309 UHS saliva collection and analysis was conducted with informed written consent following institutional
310 review board approval (ENACT – Enabling New Approaches for CoVID-19 Treatment).

311

312 **Funding**

313 This work was funded by a Department of Health and Social Care award to the University of
314 Southampton (Grant Reference Number 2020/032 (Feasibility study for city-wide testing using saliva-
315 based LAMP testing)). The views expressed are those of the authors and not necessarily those of the

316 Department of Health and Social Care. KMG is supported by the UK Medical Research Council
317 (MC_UU_12011/4), the National Institute for Health Research (NIHR Senior Investigator (NF-SI-0515-
318 10042) and NIHR Southampton Biomedical Research Centre (IS-BRC-1215-20004)) and the British
319 Heart Foundation (RG/15/17/3174). For this project, Emma Howson was on secondment at GeneSys
320 Biotech Ltd, which was part funded by The Pirbright Institute Flexible Talent Mobility Account (FTMA)
321 under BBSRC grant BB/S507945/1. The analytical testing was conducted at HHFT and at Defra
322 maintained facilities at the Animal and Plant Health Agency-Weybridge.
323

324 **References**

- 325 1 Peto Julian, Alwan Nisreen A., Godfrey Keith M., Burgess Rochelle A., Hunter David J., Riboli
326 Elio, et al. Universal weekly testing as the UK COVID-19 lockdown exit strategy. *Lancet*
327 2020;**395**(10234):1420–1. Doi: 10.1016/S0140-6736(20)30936-3.
- 328 2 PE Sax. Rapid-inexpensive-home-testing-for-covid-19-may-get-us-out-of-this-mess-before-a-
329 vaccine. Available at [https://blogs.jwatch.org/hiv-id-observations/index.php/rapid-](https://blogs.jwatch.org/hiv-id-observations/index.php/rapid-inexpensive-home-testing-for-covid-19-may-get-us-out-of-this-mess-before-a-vaccine/2020/07/05/)
330 [inexpensive-home-testing-for-covid-19-may-get-us-out-of-this-mess-before-a-](https://blogs.jwatch.org/hiv-id-observations/index.php/rapid-inexpensive-home-testing-for-covid-19-may-get-us-out-of-this-mess-before-a-vaccine/2020/07/05/)
331 [vaccine/2020/07/05/](https://blogs.jwatch.org/hiv-id-observations/index.php/rapid-inexpensive-home-testing-for-covid-19-may-get-us-out-of-this-mess-before-a-vaccine/2020/07/05/) n.d.
- 332 3 World Health Organization. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in
333 suspected human cases. Available at [https://www.who.int/publications/i/item/laboratory-](https://www.who.int/publications/i/item/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117)
334 [testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117](https://www.who.int/publications/i/item/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117) n.d.
- 335 4 Rapid Salivary Test suitable for a mass screening program to detect SARS-CoV-2: A diagnostic
336 accuracy study 2020;(January).
- 337 5 Reuters. UK has fixed swab shortage problem for coronavirus testing. Available at
338 [https://uk.reuters.com/article/uk-health-coronavirus-britain-swabs/uk-has-fixed-swab-](https://uk.reuters.com/article/uk-health-coronavirus-britain-swabs/uk-has-fixed-swab-shortage-problem-for-coronavirus-testing-minister-idUKKBN21K2SA)
339 [shortage-problem-for-coronavirus-testing-minister-idUKKBN21K2SA](https://uk.reuters.com/article/uk-health-coronavirus-britain-swabs/uk-has-fixed-swab-shortage-problem-for-coronavirus-testing-minister-idUKKBN21K2SA) n.d.
- 340 6 Wei Shan, Kohl Esther, Djandji Alexandre, Morgan Stephanie, Whittier Susan, Mansukhani
341 Mahesh, et al. Field-deployable, rapid diagnostic testing of saliva samples for SARS-CoV-2.
342 *MedRxiv* 2020:2020.06.13.20129841. Doi: 10.1101/2020.06.13.20129841.
- 343 7 Sri Santosh Tatikonda, Parmar Reshu, Anand Hanish, Srikanth Konkati, Saritha Madham. A
344 Review of Salivary Diagnostics and Its Potential Implication in Detection of Covid-19. *Cureus*
345 2020;**12**(4). Doi: 10.7759/cureus.7708.
- 346 8 Tsugunori Notomi, Okayama Hiroto, Masubuchi Harumi, Yonekawa Toshihiro, Watanabe
347 Keiko, Amino Nobuyuki, et al. Loop-mediated isothermal amplification of DNA. *Nucleic Acids*
348 *Res* 2000;**28**(12):63.
- 349 9 Keikha Masoud. *LAMP Method as One of the Best Candidates for Replacing with PCR Method.*

- 350 vol. 25. n.d.
- 351 10 Howson E. L. A., Armson B., Lyons N. A., Chepkwony E., Kasanga C. J., Kandusi S., et al. Direct
352 detection and characterization of foot-and-mouth disease virus in East Africa using a field-
353 ready real-time PCR platform. *Transbound Emerg Dis* 2018;**65**(1):221–31. Doi:
354 10.1111/tbed.12684.
- 355 11 Tsai Chi Chu, Shih Huei Chuan, Ko Ya Zhu, Wang Ren Huang, Li Shu Ju, Chiang Yu Chung. Direct
356 LAMP assay without prior DNA purification for sex determination of papaya. *Int J Mol Sci*
357 2016;**17**(10). Doi: 10.3390/ijms17101630.
- 358 12 Mahony James, Chong Sylvia, Bulir David, Ruyter Alexandra, Mwawasi Ken, Waltho Daniel.
359 Multiplex loop-mediated isothermal amplification (M-LAMP) assay for the detection of
360 influenza A/H1, A/H3 and influenza B can provide a specimen-to-result diagnosis in 40min with
361 single genome copy sensitivity. *J Clin Virol* 2013;**58**(1):127–31. Doi:
362 <https://doi.org/10.1016/j.jcv.2013.06.006>.
- 363 13 Wong Y. P., Othman S., Lau Y. L., Radu S., Chee H. Y. Loop-mediated isothermal amplification
364 (LAMP): a versatile technique for detection of micro-organisms. *J Appl Microbiol* 2018:626–43.
365 Doi: 10.1111/jam.13647.
- 366 14 Zhao Jiangtao, Feng Ruo. Sensitive and rapid detection of Zika virus by loop-mediated
367 isothermal amplification. *Virus Genes* 2019;**55**(1):43–50. Doi: 10.1007/s11262-018-1612-x.
- 368 15 Fowler Veronica L., Howson Emma L.A., Madi Mikidache, Mioulet Valérie, Caiusi Chiara,
369 Pauszek Steven J., et al. Development of a reverse transcription loop-mediated isothermal
370 amplification assay for the detection of vesicular stomatitis New Jersey virus: Use of rapid
371 molecular assays to differentiate between vesicular disease viruses. *J Virol Methods*
372 2016;**234**:123–31. Doi: 10.1016/j.jviromet.2016.04.012.
- 373 16 Armson Bryony, Walsh Charlotte, Morant Nick, Fowler Veronica L, Knowles Nick J., Clark
374 Duncan. The development of two field-ready reverse transcription loop-mediated isothermal
375 amplification assays for the rapid detection of Seneca Valley virus 1. *Transbound Emerg Dis*

- 376 2019;**66**(1):497–504. Doi: 10.1111/tbed.13051.
- 377 17 Feng Wenzhuo, Nukaya Akira, Satou Mamoru, Fukuta Naoko, Ishiguro Yasushi, Suga Haruhisa,
378 et al. Use of LAMP detection to identify potential contamination sources of plant-pathogenic
379 pythium species in hydroponic culture systems of tomato and eustoma. *Plant Dis*
380 2018;**102**(7):1357–64. Doi: 10.1094/PDIS-10-17-1679-RE.
- 381 18 Feng Wenzhuo, Hieno Ayaka, Kusunoki Mikio, Suga Haruhisa, Kageyama Koji. LAMP detection
382 of four plant-pathogenic oomycetes and its application in lettuce fields. *Plant Dis*
383 2019;**103**(2):298–307. Doi: 10.1094/PDIS-05-18-0858-RE.
- 384 19 Tomlinson Jenny, Boonham Neil. Real-Time LAMP for *Chalara fraxinea* Diagnosis. *Methods Mol*
385 *Biol* 2015;**1302**:75–83. Doi: 10.1007/978-1-4939-2620-6_6.
- 386 20 Yan Chao, Cui Jinghua, Huang Lei, Du Bing, Chen Lu, Xue Guanhua, et al. Rapid and visual
387 detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse transcription loop-mediated
388 isothermal amplification assay. *Clin Microbiol Infect* 2020. Doi: 10.1016/j.cmi.2020.04.001.
- 389 21 de Paz Héctor David, Brotons Pedro, Esteva Cristina, Muñoz-Almagro Carmen. Validation of a
390 Loop-Mediated Isothermal Amplification Assay for Rapid Diagnosis of Invasive Pneumococcal
391 Disease. *Front Cell Infect Microbiol* 2020;**10**. Doi: 10.3389/fcimb.2020.00115.
- 392 22 Fowler Veronica L, Armson Bryony, Gonzales Jose L, Wise Emma L, Howson Emma L A, Vincent-
393 Mistiaen Zoe, et al. A reverse-transcription loop-mediated isothermal amplification (RT-LAMP)
394 assay for the rapid detection of SARS-CoV-2 within nasopharyngeal and oropharyngeal swabs
395 at Hampshire Hospitals NHS Foundation Trust Keywords. *MedRxiv* 2020:2020.06.30.20142935.
396 Doi: 10.1101/2020.06.30.20142935.
- 397 23 Walsh P. Sean, Metzger David A., Higuchi Russell. Biotechniques 30th anniversary gem Chelex
398 100 as a medium for simple extraction of DNA for PCR-based typing from forensic material.
399 *Biotechniques* 2013;**54**(3):506–13.
- 400 24 Liu L., Wei Q., Alvarez X., Wang H., Du Y., Zhu H., et al. Epithelial Cells Lining Salivary Gland
401 Ducts Are Early Target Cells of Severe Acute Respiratory Syndrome Coronavirus Infection in the

- 402 Upper Respiratory Tracts of Rhesus Macaques. *J Virol* 2011;**85**(8):4025–30. Doi:
403 10.1128/jvi.02292-10.
- 404 25 Zhu Jialou, Guo Jiubiao, Xu Yuzhong, Chen Xinchun. Viral dynamics of SARS-CoV-2 in saliva from
405 infected patients. *J Infect* 2020;(xxxx):10–2. Doi: 10.1016/j.jinf.2020.06.059.
- 406 26 Azzi Lorenzo, Carcano Giulio, Gianfagna Francesco, Grossi Paolo, Dalla Daniela, Genoni Angelo,
407 et al. Saliva is a reliable tool to detect SARS-CoV-2 2020;(January).
- 408 27 Han Pingping. Saliva — Friend and Foe in the COVID-19 Outbreak 2020.
- 409 28 Azzi Lorenzo, Carcano Giulio, Dalla Gasperina Daniela, Sessa Fausto, Maurino Vittorio, Baj
410 Andreina. Two cases of COVID-19 with positive salivary and negative pharyngeal or respiratory
411 swabs at hospital discharge: a rising concern. *Oral Dis* 2020;(April):1–3. Doi:
412 10.1111/odi.13368.
- 413

Table 1. Sample preparation optimisation for direct detection of SARS-CoV-2 in crude saliva

| Treatment | Panel A: AHHFT Saliva C _T 21.08 (1:1 in Mucolyse™) | | | | | | | | Panel B: UHS Saliva C _T 24.47 (1:1 in Mucolyse™) | | | | | | Panel C: UHS Saliva C _T 25.27 (1:1 in Mucolyse™) | | | | | | | | |
|-----------------------------------|---|----------------|-------|---------|-------|-------------|-------|-------------|---|------------------------|---------|-------|-------------|-------|---|-------|------------------------|---------|-------|-------------|-------|-------------|-------|
| | Dilution | rRT-PCR | | No Heat | | 70°C 4 mins | | 98°C 2 mins | | rRT-PCR C _T | No Heat | | 70°C 4 mins | | 98°C 2 mins | | rRT-PCR C _T | No Heat | | 70°C 4 mins | | 98°C 2 mins | |
| | | C _T | Tp | Anneal | Tp | Anneal | Tp | Anneal | Tp | | Anneal | Tp | Anneal | Tp | Anneal | Tp | | Anneal | Tp | Anneal | Tp | Anneal | Tp |
| Saliva in NFW | 1 in 5 | 19.92 | | | 08:32 | 83.38 | 06:53 | 83.66 | 25.83 | | | | | | 13:21 | 83.39 | 26.39 | | | 12:14 | 83.05 | | |
| | 1 in 5 | | | | 08:15 | 83.32 | 06:59 | 83.68 | | | | | | 13:25 | 83.24 | | | | 10:26 | 83.17 | | | |
| | 1 in 10 | 19.25 | | | 08:07 | 83.30 | 07:05 | 83.53 | 26.34 | | | | | 14:38 | 83.11 | 27.97 | | | | | | | |
| | 1 in 10 | | | | 07:35 | 83.40 | 06:56 | 83.55 | | | | | | 13:06 | 83.41 | | | | 11:48 | 83.13 | | | |
| | 1 in 20 | 19.75 | 12:28 | 83.56 | 07:50 | 83.33 | 07:20 | 83.47 | 26.21 | 12:09 | 83.65 | | | 10:00 | 83.29 | 28.98 | | | | | | | |
| | 1 in 20 | | | | 08:08 | 83.39 | 07:37 | 83.52 | | | | | | 09:38 | 83.34 | | | | | | | | |
| | 1 in 40 | 20.41 | 09:16 | 83.65 | 08:45 | 83.37 | 07:32 | 83.65 | 27.24 | | | | | 13:46 | 83.25 | 30.36 | | | 14:29 | 83.81 | | | |
| | 1 in 40 | | 10:40 | 83.59 | 08:54 | 83.29 | 07:34 | 83.54 | | | | | | | | | | | | | | | |
| | 1 in 80 | 21.32 | 09:08 | 83.75 | 08:43 | 84.02 | 08:18 | 83.69 | 28.15 | | | | | | | 31.22 | | | | | | | |
| | 1 in 80 | | 09:27 | 83.71 | 08:25 | 83.94 | 07:57 | 83.60 | | | | | | | | | 11:42 | 83.08 | | | | | |
| | 1 in 160 | 22.66 | 08:21 | 83.70 | 10:15 | 83.95 | 08:10 | 83.62 | 30.09 | | | | | | | 32.17 | | | | | | | |
| | 1 in 160 | | 08:25 | 83.62 | 10:57 | 84.00 | 09:47 | 83.59 | | | | | | | | | | | | | | | |
| 1 in 320 | 23.58 | 08:30 | 83.63 | 09:21 | 83.71 | 10:07 | 83.60 | 30.95 | | | | | | | 33.86 | 12:17 | 83.09 | | | | | | |
| 1 in 320 | | 09:19 | 83.66 | 08:41 | 83.73 | 09:36 | 83.67 | | | | | | | | | | | | | | | | |
| 1 in 640 | 23.99 | 09:42 | 83.66 | 08:54 | 83.01 | | | 31.83 | | | | | | | 34.70 | | | | | | | | |
| 1 in 640 | | 08:28 | 83.66 | 08:38 | 83.97 | 08:25 | 83.68 | | | | | | | | | | | | | | | | |
| Saliva in 10% (w/v) Chelex® Resin | 1 in 5 | 18.84 | | | 06:05 | 83.69 | 05:43 | 83.73 | 25.97 | | | | | 08:31 | 83.83 | 28.23 | | | 09:18 | 83.39 | | | |
| | 1 in 5 | | 14:32 | 83.50 | 06:09 | 83.67 | 05:47 | 83.68 | | | | | 10:17 | 83.40 | 12:16 | | 83.60 | | | 08:35 | 83.35 | | |
| | 1 in 10 | 19.22 | 08:51 | 83.58 | 06:07 | 83.54 | 05:54 | 83.70 | 26.34 | | | 09:24 | 83.30 | 09:02 | 83.36 | 29.96 | | | 09:37 | 83.32 | | | |
| | 1 in 10 | | 09:47 | 83.56 | 06:07 | 83.56 | 05:56 | 83.65 | | | 11:21 | 83.27 | 09:32 | 83.31 | 08:17 | | 83.31 | | 09:29 | 83.13 | 10:22 | 83.22 | 08:53 |
| | 1 in 20 | 19.7 | 07:44 | 83.52 | 06:15 | 83.43 | 06:03 | 83.61 | 27.02 | 12:45 | 83.19 | 08:30 | 83.31 | 08:20 | 83.23 | 30.17 | | | 09:20 | 83.19 | | | |
| | 1 in 20 | | 08:38 | 83.55 | 06:11 | 83.62 | 06:05 | 83.72 | | | 12:57 | 83.28 | 09:49 | 83.40 | 08:29 | | 83.35 | | | 13:10 | 83.06 | 10:36 | 83.16 |
| | 1 in 40 | 21.08 | 08:14 | 83.61 | 06:18 | 83.62 | 06:07 | 83.68 | 28.27 | | | 12:57 | 83.52 | 07:59 | 83.33 | 31.39 | 12:19 | 83.05 | | | 09:44 | 83.15 | |
| | 1 in 40 | | 07:37 | 83.52 | 06:18 | 83.56 | 06:13 | 83.67 | | | | | 08:46 | 83.32 | 14:06 | | 83.32 | | 12:52 | 83.05 | 08:48 | 83.12 | 10:20 |
| | 1 in 80 | 22.25 | 07:37 | 83.87 | 06:29 | 83.82 | 06:32 | 83.62 | 28.47 | | | | 11:51 | 83.32 | 10:50 | 83.35 | 32.43 | 11:19 | 83.05 | | | | |
| | 1 in 80 | | 07:38 | 83.03 | 06:31 | 83.75 | 06:37 | 83.60 | | | | | 10:25 | 83.31 | | | | | | 09:25 | 83.26 | 08:11 | 83.44 |
| | 1 in 160 | 23.05 | 07:47 | 83.56 | 06:57 | 83.74 | 06:51 | 83.61 | 29.52 | | | | | 10:41 | 83.41 | 33.88 | | | | | | | |
| | 1 in 160 | | 07:32 | 83.53 | 06:47 | 83.65 | 06:52 | 83.59 | | | | | 13:10 | 83.15 | 09:46 | | 83.41 | | | | | | |
| 1 in 320 | 24.05 | 08:00 | 83.58 | 07:02 | 83.68 | 07:08 | 83.60 | 30.26 | | | | | | 13:22 | 83.28 | 34.98 | | | | | | | |
| 1 in 320 | | 08:03 | 83.58 | 07:27 | 83.68 | 07:15 | 83.60 | | | | | | | | | | | | | | | | |
| 1 in 640 | 24.6 | 08:12 | 83.61 | 07:25 | 83.66 | 07:32 | 83.65 | 31.55 | | | | | | | 34.98 | | | | | | | | |
| 1 in 640 | | 08:33 | 83.60 | 08:04 | 83.58 | 07:22 | 83.63 | | | | | | | 12:10 | | 83.23 | | | | | | | |

HHFT: Hampshire Hospitals NHS Foundation Trust; UHS: University Hospital Southampton; NFW: Nuclease free water; C_T: Cycle Threshold; Tp: Time to positivity. Dark grey shading indicates samples positive in duplicates by direct RT-LAMP, Light grey shading indicates samples positive in single replicates. Blank wells represent no amplification detected (negative) in Direct RT-LAMP. For Tp 00:00 represents minutes:seconds.

Table 2: Dilution series of inactivated whole virus spiked into pooled saliva from 25 negative patient samples (no predilution 1:1 in Mucolyse™)

| Treatment | Dilution | No Heat | | | 70°C 4 mins | | | 98°C 2 mins | | |
|--|----------|------------------------|-------|--------|------------------------|-------|--------|------------------------|-------|--------|
| | | rRT-PCR C _T | Tp | Anneal | rRT-PCR C _T | Tp | Anneal | rRT-PCR C _T | Tp | Anneal |
| Saliva in NFW | 1 in 5 | 24.19 | | | 21.37 | | | 22.04 | 09:40 | 83.53 |
| | 1 in 5 | | | | | 11:57 | 83.25 | | 12:37 | 83.33 |
| | 1 in 10 | 20.39 | | | 22.23 | 10:09 | 83.34 | 22.25 | 11:03 | 83.77 |
| | 1 in 10 | | 12:23 | 83.11 | | 09:58 | 83.34 | | 11:39 | 83.22 |
| | 1 in 20 | 21.21 | | | 23.21 | 09:24 | 83.30 | 23.07 | 11:16 | 83.33 |
| | 1 in 20 | | 12:55 | 83.16 | | 09:53 | 83.35 | | | |
| 1 in 40 | 22.64 | | | 24.62 | 11:54 | 83.40 | 24.83 | 14:29 | 83.15 | |
| 1 in 40 | | 10:02 | 83.33 | | 09:16 | 83.45 | | | | |
| Saliva in 10% (w/v) Chelex® 100 Resin | 1 in 5 | 23.71 | | | 21.48 | | | 22.96 | 08:07 | 83.57 |
| | 1 in 5 | | | | | 11:02 | 83.32 | | 07:51 | 83.48 |
| | 1 in 10 | 19.78 | | | 22.95 | 09:04 | 83.37 | 20.8 | 08:17 | 83.46 |
| | 1 in 10 | | 12:01 | 83.24 | | 09:17 | 83.33 | | 07:35 | 83.38 |
| | 1 in 20 | 21.08 | | | 23.22 | 10:55 | 83.28 | 23.09 | 07:54 | 83.35 |
| | 1 in 20 | | 10:20 | 83.24 | | 08:35 | 83.35 | | 08:13 | 83.39 |
| | 1 in 40 | 21.85 | | | 23.92 | 09:21 | 83.30 | 23.89 | 08:48 | 83.62 |
| | 1 in 40 | | 09:16 | 83.32 | | 10:08 | 83.27 | | 08:04 | 83.54 |

NFW: Nuclease free water; C_T: Cycle Threshold; Tp: Time to positivity. Dark grey shading indicates samples positive in duplicates by direct RT-LAMP, Light grey shading indicates samples positive in single replicates. Blank wells represent no amplification detected (negative) in Direct RT-LAMP. For Tp 00:00 represents minutes:seconds.

Table 3: Dilution series of inactivated whole virus spiked into pooled saliva from five negative patient samples (predilution 1:1 in Mucolyse™)

| Treatment | Dilution | No Heat (spiked sample 1:1 in Mucolyse™) | | | 70°C 4 mins (spiked sample 1:1 in Mucolyse™) | | | 98°C 2 mins (spiked sample 1:1 in Mucolyse™) | | |
|---------------------------------------|----------|--|-------|--------|--|-------|--------|--|-------|--------|
| | | rRT-PCR C _T | Tp | Anneal | rRT-PCR C _T | Tp | Anneal | rRT-PCR C _T | Tp | Anneal |
| Saliva in NFW | 1 in 5 | 21.97 | | | 21.97 | 11:31 | 83.63 | 21.97 | 09:01 | 83.41 |
| | 1 in 5 | | | | | 10:30 | 83.48 | | 09:34 | 83.39 |
| | 1 in 10 | 22.32 | | | 22.32 | 13:36 | 83.42 | 22.32 | 09:37 | 83.36 |
| | 1 in 10 | | | | | 10:11 | 83.39 | | 11:31 | 83.29 |
| | 1 in 20 | 23.67 | | | 23.67 | 10:14 | 83.20 | 23.67 | 11:52 | 83.23 |
| | 1 in 20 | | | | | | | | | |
| | 1 in 40 | 24.32 | | | 24.32 | 10:15 | 83.60 | 24.32 | 08:44 | 83.44 |
| | 1 in 40 | | 12:38 | 83.37 | | | | | 10:38 | 83.40 |
| | 1 in 80 | 25.30 | 09:55 | 83.58 | 25.30 | 09:30 | 83.35 | 25.30 | 14:58 | 83.37 |
| | 1 in 80 | | 09:06 | 83.44 | | 09:42 | 83.35 | | | |
| | 1 in 160 | 26.81 | | | 26.81 | | | 26.81 | 14:05 | 83.32 |
| | 1 in 160 | | | | | | | | | |
| 1 in 320 | 28.77 | | | 28.77 | | | 28.77 | | | |
| 1 in 320 | | | | | | | | | | |
| 1 in 640 | 29.72 | 10:10 | 83.63 | 29.72 | | | 29.72 | | | |
| 1 in 640 | | | | | | | | | | |
| 1 in 1280 | 29.85 | | | 29.85 | | | 29.85 | | | |
| 1 in 1280 | | | | | | | | | | |
| Saliva in 10% (w/v) Chelex® 100 Resin | 1 in 5 | 22.49 | | | 22.49 | 07:21 | 83.68 | 22.49 | 07:11 | 83.50 |
| | 1 in 5 | | | | | 07:34 | 83.54 | | 07:43 | 83.41 |
| | 1 in 10 | 23.17 | | | 23.17 | 07:48 | 83.58 | 23.17 | 10:06 | 83.40 |
| | 1 in 10 | | | | | 08:16 | 83.45 | | 08:32 | 83.35 |
| | 1 in 20 | 24.33 | 10:11 | 83.58 | 24.33 | 07:41 | 83.43 | 24.33 | 08:42 | 83.35 |
| | 1 in 20 | | 10:20 | 83.59 | | 07:41 | 83.46 | | 08:39 | 83.40 |
| | 1 in 40 | 25.50 | 12:30 | 83.53 | 25.50 | 08:05 | 83.45 | 25.50 | 08:38 | 83.41 |
| | 1 in 40 | | 11:52 | 83.38 | | 08:07 | 83.28 | | 07:55 | 83.32 |
| | 1 in 80 | 26.63 | 07:59 | 83.67 | 26.63 | 10:42 | 83.52 | 26.63 | 10:47 | 83.32 |
| | 1 in 80 | | 09:34 | 83.56 | | 09:05 | 83.41 | | 10:45 | 83.24 |
| | 1 in 160 | 26.43 | 11:14 | 83.54 | 26.43 | 10:00 | 83.48 | 26.43 | 10:22 | 83.23 |
| | 1 in 160 | | | | | 09:50 | 83.40 | | 10:26 | 83.22 |
| 1 in 320 | 27.31 | | | 27.31 | 09:35 | 83.55 | 27.31 | | | |
| 1 in 320 | | | | | | | | | | |
| 1 in 640 | 28.56 | | | 28.56 | 09:00 | 83.59 | 28.56 | 09:35 | 83.37 | |
| 1 in 640 | | | | | | | | | | |
| 1 in 1280 | 29.26 | | | 29.26 | | | 29.26 | | | |
| 1 in 1280 | | | | | | | | | | |

NFW: Nuclease free water; C_T: Cycle Threshold; Tp: Time to positivity. Dark grey shading indicates samples positive in duplicates by direct RT-LAMP, Light grey shading indicates samples positive in single replicates. Blank wells represent no amplification detected (negative) in Direct RT-LAMP. For Tp 00:00 represents minutes:seconds.